DALLAS, Sept. 9, 2024
DALLAS, Sept. 9, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the Retina Society 57th�Annual Scientific Meeting and at Advanced Therapies Europe taking place during the 2nd week of September in Lisbon, Portugal. Details for the presentations are as follows:
Advertisement
Title:�BCVA Analysis of Patients Treated with Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 100-week TOPLINE Results from a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE)Session Title: Genetic Diseases, Dystrophies & DegenerationsSession Date:�September 11, 2024Session Time:�4:25 p.m. WESTLocation:�Pedro Leitao Ballroom, Four Seasons Hotel Ritz, LisbonPresenter:�Anat Loewenstein, MD, MHA, Professor and Director, Division of Ophthalmol., Tel Aviv University
Advertisement
In her presentation, Dr. Loewenstein will highlight the end-of-study 100 week RESTORE data from mutation-agnostic Multi-Characteristic Opsin (MCO) therapy of severe vision loss due to retinitis pigmentosa.
Title:�Democratizing Gene Therapy for Neurodegenerative DiseasesSession Title:� Gene Therapy: Spotlight on Developments and BreakthroughsSession Date: September 11, 2024Session Time:�4:15 p.m. WESTLocation:�Estoril Convention Center, LisbonPresenter:�Samarendra Mohanty, PhD, President & Chief Scientific Officer
During his presentation, Dr. Mohanty will highlight the recent developments and breakthroughs on mutation-agnostic optogenetic gene therapy for vision restoration in inherited retinal dystrophies, and image-guided spatially targeted laser gene delivery platform for treating geographic atrophy. The presentation will be followed by a panel discussion at 4:45 pm. Dr. Mohanty will also chair a session titled "Flexibility in Action: Harnessing Adaptive Vector Platforms for Gene Therapy Manufacturing" on�September 12, 2024, from 1:45 - 3: 00 p.m. WEST.
About�Nanoscope Therapeutics Inc.Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase�2b�multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also completed the Phase 2 STARLIGHT trial� of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.
Investor Contact:Argot Partners(212) [email protected]�
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon-302241279.html
SOURCE Nanoscope Therapeutics
